By a News Reporter-Staff News Editor at Drug Week A patent application by the inventor Yamaguchi, Masayoshi (Shizuoka City, JP), filed on October 14, 2016, was made available online on May 4, 2017, according to news reporting originating from Washington, D.C., by NewsRx correspondents (see also Primus Pharmaceuticals, Inc.).
This patent application is assigned to Primus Pharmaceuticals, Inc.
The following quote was obtained by the news editors from the background information supplied by the inventors: "Flavonoids are a diverse class of compounds found in a large variety of plants and herbs that have shown some benefit on human health. For example, U.S. Patent Publication 2013/0210753 describes methods for treating muscular dystrophies using flavonoids.
"Baicalin and catechin are two types of flavonoids. Baicalin and catechin are the principal active ingredients in Limbrel.RTM., a medical food marketed by Primus Pharmaceuticals, Inc., Scottsdale Ariz., for the management of metabolic processes that underlie osteoarthritis. Limbrel.RTM. is supplied as an oral capsule, and contains from 250 to 500 mg of baicalin and catechin combined, for administration once or twice daily.
".beta.-Caryophyllene is a natural sesquiterpene found in the essential oils of a variety of plants, including clove, hemp Cannabis sativa, rosemary Rosmarinus oficinalis, Cinnamonum sp. (cinnamon) and hops. .beta.-Caryophyllene has been approved as a food additive by the United States Food and Drug Administration (FDA), and is widely used in foods as a flavor and aroma enhancer.
"The aim of this work was to investigate the effects of a sesquiterpene such as .beta.-Caryophyllene, baicalin, (+)-catechin and other plant derived substances on RAW267.4 cells (macrophage) in vitro, and to develop a method and a pharmaceutical formulation that can effectively treat inflammation."
In addition to the background information obtained for this patent application, NewsRx journalists also obtained the inventor's summary information for this patent application: "It has surprisingly been discovered that the combination of sesquiterpenes such as .beta.-caryophyllene, baicalin, and catechin is synergistically effective at reducing proliferation of inflammatory cells, and can be used in the treatment of numerous diseases in which inflammation is involved, including osteoarthritis and rheumatoid arthritis. Based on this discovery, numerous products and methods of treatment are now possible.
"One aspect of the present invention relates to a pharmaceutical formulation or unit dosage form for the treatment or management of inflammatory processes. The pharmaceutical formulation or unit dosage form includes therapeutically effective amounts of a sesquiterpene such as .beta.-caryophyllene and two flavonoids, preferably baicalin and catechin.
"Another aspect of the present invention relates to a method of treating inflammation or managing inflammatory processes in a human being in need thereof. The method includes administering to the human being a pharmaceutical formulation or unit dosage form comprising therapeutically effective amounts of a sesquiterpene such as .beta.-caryophyllene and two flavonoids, preferably baicalin and catechin.
"Additional advantages of the invention are set forth in part in the description which follows, and in part will be obvious from the description, or may be learned by practice of the invention. The advantages of the invention will be realized and attained by means of the elements and combinations particularly pointed out in the appended claims. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed."
URL and more information on this patent application, see: Yamaguchi, Masayoshi. Therapeutic Combinations of Sesquiterpenes and Flavonoids. Filed October 14, 2016 and posted May 4, 2017. Patent URL: http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220170112802%22.PGNR.&OS=DN/20170112802&RS=DN/20170112802
Keywords for this news article include: Primus Pharmaceuticals Inc., Therapy, Dosage Forms, Sesquiterpenes.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC